Companies · Hardware / Semiconductors

PreDxion BioSummer 2017Inactive

South San Francisco · CA, USA · Hardware / Semiconductors · founded 2017 · http://www.predxionbio.com

Diligence memoA one-page analyst read on PreDxion Bio — recommendation, valuation, rhythm, risks.
Total raised · real
0
Rounds
Latest step-up
Top 53%
Sector rank · raised
Latest stage · inferred

PreDxion Bio: limited disclosed financing to assess.

Synthesized from the figures below est. — every claim rests on a number shown on this page.

Where it sits in Hardware / Semiconductors

PreDxion Bio is one of 130 Hardware / Semiconductors companies tracked from South San Francisco, CA, USA, on record since 2017. By capital raised it ranks mid-pack (ahead of 48% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst

Rapid, scalable diagnostic for SARS-CoV-2 and beyond

PreDxion Bio is working on a rapid saliva-based antigen test for the detection of SARS-CoV-2 S-protein in asymptomatic and presymptomatic patients. Our technology is uniquely capable of being scaled to 10's of millions of tests of days using semiconductor fab processes, a scale of testing necessary to better inform public health officials and policymakers and enable contact tracing at scale. PreDxion Bio's origins are in critical care: our original technology is a rapid, near real-time cytokine and biomarker detection platform to monitor the immune response of critically-ill patients. This technology leverages a novel sensor platform we spun out of the University of Michigan. PreDxion Bio has received FDA Breakthrough Device designation and partnered with top pharmcos to monitor the immune response following CAR-T therapy and predict the development of cytokine release syndrome and neurological AEs, and for use in guiding precision medicine approaches in critical care.

COVID-19MicrofluidicsNanosensorshardware/semi
Find PreDxion Bio online

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

Financing ladder & sequence gaps

No staged rounds to sequence.

Modeled valuation trajectory
Base estimate est.
Conservative case
Upside case
Modeled post-money

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Financing rhythm
Avg between rounds
Capital velocity
On record since
First round
0
Rounds on file
How it compares to the market

Benchmarked against 130 companies in Hardware / Semiconductors. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)
This company
Sector median$8.3M
Modeled value — vs sector median (estimate, all stages)
This company
Sector median$26.4M

Raised more than 48% of sector peers (real $). Modeled value above 48% of peers (estimate).

Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
No rounds recorded.
Intelligence
Modeled next raise
Modeled next size est.
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Registry & provenance

PreDxion Bio is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
AccessOwlHardware / Semiconductorssame sector
ACCO Semiconductor, Inc.Hardware / SemiconductorsSeries A$55.1M$123.3Msame sector
ActiveloopHardware / Semiconductorssame sector
Advanced Silicon Group, Inc.Hardware / SemiconductorsSeed$1.0M$14.6Msame sector
AeroFSHardware / Semiconductorssame sector
AfrostreamHardware / Semiconductorssame sector
Aisle50Hardware / Semiconductorssame sector
AKHAN Semiconductor, Inc.Hardware / SemiconductorsSeries B$26.0M$207.5Msame sector
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Correlia Biosystems, Inc.
Next-gen blood testing to provide 1000x more data to pharma companies
BiotechnologySeries A$11.6M74%
Shield Bio
Bringing 3rd generation, nanopore sequencing to healthcare to solve…
Biotech / Pharma74%
Pardes Biosciences, Inc
We break viruses
BiotechnologySeries C$1.7B74%
Biobot Analytics, Inc.
Population health analytics powered by wastewater.
Software / TechSeries B$73.4M74%
Cofactor Genomics, Inc.
Cofactor closes the precision medicine gap with predictive diagnostics
BiotechnologySeries A$9.7M73%
Signatur Biosciences
Simple tests for complex diseases.
Biotech72%
Digistain
Pioneering Breast Cancer Diagnostics for a Healthier Tomorrow
Medical Devices72%
InnaMed
At-home blood testing: measure + analyze + enhance.
Biotech72%
Frequently asked
What does PreDxion Bio do and where is it based?
PreDxion Bio operates in the Hardware / Semiconductors sector, based in South San Francisco, CA, USA. Rapid, scalable diagnostic for SARS-CoV-2 and beyond
Explore related

See where PreDxion Bio sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at PreDxion Bio, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.